Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

STIMBullishIndustry Newsnews

High materiality9/10

Neuronetics surge from Greenbrook TMS deal; BTIG sets $5 target

Jul 20, 2026, 2:41 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive execution of a transformative acquisition, corroborated by a beat-and-raise narrative, BTIG upgrade, and immediate 28% stock move; multiple new growth vectors (TMS + Spravato) could re-rate valuation, despite ongoing execution and reimbursement risks.

AI summary

What happened, with direct paths to the underlying reporting

Neuronetics' Greenbrook TMS acquisition transforms it into a vertically integrated mental-health platform, adding TMS and Spravato. The Q1 beat and BTIG's Buy rating with a $5 target underscore near-term upside as the company expands. Strategic partnerships with Compass and ANT Neuro highlight growth in interventional therapies, though reimbursement and integration risks remain.

Neuronetics jumped about 28% after Greenbrook TMS acquisition.
New platform adds TMS and Spravato, expanding mood-treatment offerings.
Q1: loss 16c vs 17c, revenue $34.454M vs $34.183M consensus.
BTIG initiates Buy with a $5 target based on 2.5x sales.
Compass Pathways and ANT Neuro partnerships broaden interventional-therapy pipeline.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Neuronetics surge from Greenbrook TMS deal; BTIG sets $5 target

Neuronetics (STIM) Inks a New Merger Agreement With Greenbrook